CLOSED-LOOP CONTROL IN STEADY-STATE CONDITIONS
Techniques disclosed herein relate to closed-loop control in steady-state conditions. In some embodiments, the techniques may involve determining an amount of unmetabolized therapeutic substance in a patient; determining, based on a measurement of a physiological condition of the patient and a target value for the physiological condition, a first amount or rate of a basal dosage for delivery to the patient; adjusting, based on the amount of unmetabolized therapeutic substance, the first amount or rate of the basal dosage to determine a second amount or rate of the basal dosage; and causing delivery of the second amount or rate of the basal dosage based on communicating the second amount or rate in a delivery command.
1 . A processor-implemented method for closed-loop control in steady-state conditions, the method comprising:
determining an amount of unmetabolized therapeutic substance in a patient;
determining, based on a recent measurement of a physiological condition of the patient and a target value for the physiological condition, a first amount or rate of a basal dosage for delivery to the patient;
adjusting, based on the amount of unmetabolized therapeutic substance, the first amount or rate of the basal dosage to determine a second amount or rate of the basal dosage; and
causing delivery of the second amount or rate of the basal dosage based on communicating the second amount or rate in a delivery command.
2 . The method of claim 1 , wherein the amount of unmetabolized therapeutic substance is determined based on one or more pharmacokinetic models.
3 . The method of claim 1 , wherein determining the amount of unmetabolized therapeutic substance comprises generating data based on filtering historical delivery data to exclude historical basal information.
4 . The method of claim 1 , wherein determining the first amount or rate of the basal dosage comprises using a proportional-integral-derivative (PID) closed-loop control process.
5 . The method of claim 4 , wherein an integral path of the PID closed-loop control process comprises an upper limit equal to a maximum amount or rate for the basal dosage.
6 . The method of claim 5 , wherein the maximum amount or rate for the basal dosage is patient-specific.
7 . The method of claim 1 , wherein the first amount or rate of the basal dosage is less than the amount of unmetabolized therapeutic substance, and wherein causing delivery of the second amount or rate of the basal dosage comprises causing suspended delivery of any basal dosages.
8 . A system for closed-loop control in steady-state conditions, the system comprising:
one or more processors; and
one or more processor-readable storage media storing instructions which, when executed by the one or more processors, cause performance of:
determining an amount of unmetabolized therapeutic substance in a patient;
determining, based on a recent measurement of a physiological condition of the patient and a target value for the physiological condition, a first amount or rate of a basal dosage for delivery to the patient;
adjusting, based on the amount of unmetabolized therapeutic substance, the first amount or rate of the basal dosage to determine a second amount or rate of the basal dosage; and
causing delivery of the second amount or rate of the basal dosage based on communicating the second amount or rate in a delivery command.
9 . The system of claim 8 , wherein the amount of unmetabolized therapeutic substance is determined based on one or more pharmacokinetic models.
10 . The system of claim 8 , wherein determining the amount of unmetabolized therapeutic substance comprises generating data based on filtering historical delivery data to exclude historical basal information.
11 . The system of claim 8 , wherein determining the first amount or rate of the basal dosage comprises using a proportional-integral-derivative (PID) closed-loop control process.
12 . The system of claim 11 , wherein an integral path of the PID closed-loop control process comprises an upper limit equal to a maximum amount or rate for the basal dosage.
13 . The system of claim 12 , wherein the maximum amount or rate for the basal dosage is patient-specific.
14 . The system of claim 8 , wherein the first amount or rate of the basal dosage is less than the amount of unmetabolized therapeutic substance, and wherein causing delivery of the second amount or rate of the basal dosage comprises causing suspended delivery of any basal dosages.
15 . One or more non-transitory processor-readable storage media storing instructions which, when executed by one or more processors, cause performance of:
determining an amount of unmetabolized therapeutic substance in a patient;
determining, based on a recent measurement of a physiological condition of the patient and a target value for the physiological condition, a first amount or rate of a basal dosage for delivery to the patient;
adjusting, based on the amount of unmetabolized therapeutic substance, the first amount or rate of the basal dosage to determine a second amount or rate of the basal dosage; and
causing delivery of the second amount or rate of the basal dosage based on communicating the second amount or rate in a delivery command.
16 . The one or more non-transitory processor-readable storage media of claim 15 , wherein the amount of unmetabolized therapeutic substance is determined based on one or more pharmacokinetic models.
17 . The one or more non-transitory processor-readable storage media of claim 15 , wherein determining the amount of unmetabolized therapeutic substance comprises generating data based on filtering historical delivery data to exclude historical basal information.
18 . The one or more non-transitory processor-readable storage media of claim 15 , wherein determining the first amount or rate of the basal dosage comprises using a proportional-integral-derivative (PID) closed-loop control process.
19 . The one or more non-transitory processor-readable storage media of claim 18 , wherein an integral path of the PID closed-loop control process comprises an upper limit equal to a maximum amount or rate for the basal dosage.
20 . The one or more non-transitory processor-readable storage media of claim 15 , wherein the first amount or rate of the basal dosage is less than the amount of unmetabolized therapeutic substance, and wherein causing delivery of the second amount or rate of the basal dosage comprises causing suspended delivery of any basal dosages.